PAHC Stock Analysis: Buy, Sell, or Hold?
PAHC - Phibro Animal Health Corporation Class A
$30.53
-0.54 (-1.74%)
▼
5d:
-5.42%
30d:
-8.76%
90d:
-43.25%
HOLD
LOW Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 26, 2026
Get Alerted When PAHC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: PAHC shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: PAHC shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$65.32
Based on 6.5% avg growth
INTRINSIC VALUE TODAY
$40.56
24.7% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PAHC is currently trading at $30.53, which is considered oversold relative to its 30-day fair value range of $30.71 to $33.49. From a valuation perspective, the stock is trading at a discount (Forward PE: 9.1) compared to its historical average (14.3). Remarkably, the market is currently pricing in an annual earnings decline of 13.9% over the next few years. This pessimistic expectation contrasts with the company's recent 15.7% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, PAHC is in a strong downtrend. The price is currently testing key support at $30.61. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $45.60 (+49.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PAHC is in a strong downtrend. The price is currently testing key support at $30.61. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $45.60 (+49.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$30.71 -
$33.49
Company Quality Score
58/100
(HOLD)
Options IV Signal
52th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
77.7%
Protect Your Profits
Holding PAHC? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 52th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 49.4% below Wall St target ($45.60)
- CAUTION: Recommendation downgraded due to -5.4% 5-day decline
Trading Range Analysis
30-Day Trading Range
$30.71 -
$33.49
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$3.19
(10.4%)
Support & Resistance Levels
Support Level
$30.61
Resistance Level
$33.10
Current Trend
Strong Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.13
Wall Street Target
$45.60
(+49.4%)
Revenue Growth (YoY)
10.3%
Earnings Growth (YoY)
15.7%
Profit Margin
6.3%
Valuation Discount vs History
-13.9% cheaper
PE vs Historical
9.1 vs 14.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-13.9%
(market-implied from PE analysis)
1-Year Target
$27.48
(-10%)
2-Year Target
$24.73
(-19%)
3-Year Target
$22.26
(-27%)
3-Yr Target (if PE normalizes)
(PE: 9→14)
$34.86
(+14%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 8.9%)
$93.93
(+208%)
Base:
(SPY PE: 9.1, Growth: 8.9%)
$39.37
(+29%)
Bear:
(PE: 7.8, Growth: 8.9%)
$33.47
(+10%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (13x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Trailing PE: 13.33 | Current EPS (TTM): $2.33
Bull Case
$49.05
(+61%)
Analyst growth 43.5%, PE expands to 14.7
Base Case
$44.59
(+46%)
Market implied 43.5%, PE stable at 13.3
Bear Case
$21.13
(-31%)
Severe decline -20.0%, PE contracts to 11.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.1 to 14.3
Stabilization Target:
$47.82
(+56.6%)
PE Expansion Potential:
+56.6%
Share & Embed Analysis
Last updated: June 23, 2026 7:53 PM ET
Data refreshes hourly during market hours. Next update: 8:53 PM
Data refreshes hourly during market hours. Next update: 8:53 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PAHC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Jack Bendheim
SELL
7040 shares
2026-04-22
Jack Bendheim
SELL
7040 shares
2026-04-16
Jack Bendheim
SELL
7040 shares
2026-04-14
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 60 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 64 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 67 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 58 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 57 HOLD |
Advanced PAHC Option Strategies
Professional options setups generated by AI based on today's PAHC price and gamma walls.
